Real‐World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia
In this real-world study, avatrombopag was highly effective at both improving platelet counts and reducing bleeding in children with ITP, even in patients with secondary ITP or who had failed other TPO-RAs.
Authors
- Caitlin Montcrieff (ORCID: https://orcid.org/0000-0002-3540-9426)
- Rachael F. Grace (ORCID: https://orcid.org/0000-0001-7302-0449)
- Michele P. Lambert (ORCID: https://orcid.org/0000-0003-0439-402X)
- Emily Harris (ORCID: https://orcid.org/0000-0001-8583-6939)
- Candelaria O’Farrell (ORCID: https://orcid.org/0009-0003-6433-0236)
- Amanda B. Grimes (ORCID: https://orcid.org/0000-0003-2842-9266)
- Praharsha Konde (ORCID: https://orcid.org/0009-0002-7022-2891)
Institutions
- Children's Hospital of Philadelphia (US)
- Harvard University (US)
- Baylor College of Medicine (US)
- Children's Cancer Center (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1002/pbc.32143
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00